Recombinant Human CD33 Molecule, Fc Chimera

• Cat.No.: CD33-459H
• Product Overview: Recombinant Human Siglec-3 was fused to the Fc region of human IgG1 (aa 93-330). The chimeric protein was expressed in modifiedhuman 293 cells.

Specification

• Species: Human
• Source: HEK293
• Tag: Fc
• Description: Siglecs (or sialic acid-binding immunoglobulin superfamily lectins) are sialic acid-binding Ig-like lectins characterized by a homologous N-terminal V-set Ig-like domain and varying numbers of C2-set Ig-like domains. In humans 11 Siglecs have been described. Siglec-3 (CD33) is the smallest Siglec, with only 2 of these C2-set Ig domains. Siglec-3 is a 67 kDa glycoprotein found predominantly on myeloid cells, including early myeloid precursors in the bone marrow and certain subsets of mature circulating myeloid cells. Siglec-3 has also been reported on dendritic cells, cord blood-derived natural killer (NK) cells, in vitro expanded T cells, and some biphenotypic leukemias. Siglec-3 was initially described as a marker for normal and leukemic myeloid progenitor cells, but has received renewed interest due to its demonstrated lectin activity for alpha 2-6 and alpha 2-3 sialylated N-linked oligosaccharides expressed on red blood cells (RBCs) and certain myeloid cells.
• Theoretical Sequence: DPNFWLQVQESVTVQEG LCVLVPCTFFHPIPYYDKNS PVHGYWFREGAIISGDS P VAT NKLD QEVQEETQG RFRLLGDPSRNNCSLSI VDARRRDNGSYFFRMERG S T KYSYKSPQLSVH VTDLTHRPKILIPGTLE PGHSKNLTCSVSWA CE QG TPP IFS WLSAA PTSLGPRTTHSSVLIITPR PQDHGTNLTCQVKFAGA GV TT ER TIQ LN VT YV PQNPT TGIFPGD GSGKQETRAGVVH RSSNTKVDKKVEPKSCD KT HT CP PC PA PELLGG PSVFLFPPKPKDTLMI SRTPEVTCVVVDVSH EDPEVKFNWYVDGVE VH NAKTKPREEQYN STYRVVSVLTVLHQ DWLNGKEYKCKVS N KA LP AP IE KT IS KA KGQPREPQVYTLP PSRDELTKNQVSL TCLVKGFYPSDIAV EW ESN GQ PE NN YKTTPPVLDSDG SFFLYSKLTVDKS RWQQGNVFSCSV MHEALHNHYTQK SL SLSPGK.
• Molecular Mass: Siglec-3-Fc Chimera migrates as a broad band between 60 and 75 kDa on SDS-PAGE due to post-translation modifications, in particular glycosylation. This compares with the unmodified Siglec-3 - Fc Chimera that has a predicted molecular mass of 54 kDa.
• PI: Siglec-3 -Fc Chimera separates into a number of glycooforms on 2D PAGE due to post-translational modifications, in particular glycosylation. The pI range is between 6.5 and 10. This compares with the unmodified Siglec-3 - Fc Chimera that has a predicted pI of 8.3.
• %Carbohydrate: Siglec-3 - Fc Chimera consists of 10-30% carbohydrate by weight.
• Glycosylation: Siglec-3 - Fc Chimera has N-linked and may have O-linked oligosaccharides.
• Purity: >95%, as determined by SDS-PAGE and visualized by Coomassie Brilliant Blue.
• Formulation: When reconstituted in 0.5 ml sterile phosphate-buffered saline, the solution will contain 1% human serum albumin (HSA) and 10% trehalose.
• Reconstitution: It is recommended that 0.5 ml of sterile phosphate-buffered saline be added to the vial.
• Storage: Lyophilized products should be stored at 2 to 8°C. Following reconstitution short-term storage at 4°C is recommended, with longer-term storage in aliquots at -18 to -20°C.

Gene Information

• Gene Name: CD33 CD33 molecule [ Homo sapiens ]
• Synonyms: CD33 molecule; p67; SIGLEC3; FLJ00391; SIGLEC-3; CD33; CD33 antigen (gp67); CD33 antigen; gp67; Siglec-3; Sialic acid-binding Ig-like lectin 3
• Gene ID: 945
• mRNA Refseq: NM_001082618
• Protein Refseq: NP_001076087
• MIM: 159590
• UniProt ID: P20138
• Chromosome Location: 19q13.3
• Pathway: Hematopoietic cell lineage
• Function: protein binding; receptor activity; sugar binding